mybacs is a research-driven DTC company specialized in the human microbiome. Our goal is to revolutionize the market around intestinal healthcare and thus make a decisive contribution to the daily well-being of our customers. Our team of pharmaceutical scientists and physicians is focused on the development of innovative and highly-dosed synbiotic supplements. These are aligned by our singular formulations from specifically selected probiotic cultures, prebiotics as well as minerals and vitamins tailored to the individual needs of our customers.

Speedinvest is one of Europe’s most active early-stage investors, with more than €1bn AUM, 40 investors, and offices in Berlin, London, Munich, Paris, Vienna and San Francisco. Your success is our priority, so we don’t just send some money and ''check in'' at board meetings. Our mission is to empower you with game-changing support through every stage of your journey. Our focused investment teams know your industry inside and out. Their Deep Tech, Fintech, Industrial Tech, Network Effects, Digital Health and Subscriptions experience, know-how and deep networks are yours from day one. You also have full access to our in-house Platform+ team of operational experts who can provide tailored growth marketing, people (HR), US business development, and networking support throughout every stage of your journey.

Developer of financial process automation software designed to help banking and mortgage clients to expand their markets. The company's platform offers a unified digital experience, seamlessly linking business, regulatory, and servicing processes with all bank channels, while automating operations, enabling financial and insurance firms to increase productivity and reduce costs.

PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.

S3 Connected Health helps you leverage digital technologies to make a real difference to healthcare outcomes. S3 Connected Health breadth of experience across therapy areas, technologies and territories means they can truly be your global partner delivering scalable solutions that make a difference.

Businesses and individuals considering investment into Cyprus have a partner on the ground at all stages of the investment cycle. Invest Cyprus is a non-profit national body and the government’s dedicated partner responsible for attracting and facilitating Foreign Direct Investment in key economic sectors. Being the lead agent in establishing Cyprus as a world-class investment destination, Invest Cyprus proactively promotes the enhancement of the country’s competitive environment, advocating reform and maximising FDI, for the economic and social benefit of Cyprus. In close collaboration with all government authorities, public institutions and the private sector, Invest Cyprus is the investor’s first point of contact. Invest Cyprus is a member of the World Association of Investment Promotion Agencies (WAIPA) and the Mediterranean Investment Network, ANIMA

Dieter von Holtzbrinck Ventures (DvH Ventures) is one of the leading European early-stage investors. As an independent venture capitalist, DvH Ventures invests in young technology companies, building successful investment clusters in areas such as digital health, education and fintech. In addition to capital, DvH Ventures supports companies with management expertise and an international investor network. An exclusive media-for-equity program also offers access to strong brands such as Handelsblatt, DIE ZEIT, WirtschaftsWoche and Apotheken Umschau, and thus an enormous reach into the respective target groups. DvH Ventures was founded in 2014 and today manages various venture capital funds from its offices in Cologne and Vienna. Managing partners are Peter Richarz and Fabian von Trotha.

Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.

Dieter von Holtzbrinck Ventures (DvH Ventures) is one of the leading European early-stage investors. As an independent venture capitalist, DvH Ventures invests in young technology companies, building successful investment clusters in areas such as digital health, education and fintech. In addition to capital, DvH Ventures supports companies with management expertise and an international investor network. An exclusive media-for-equity program also offers access to strong brands such as Handelsblatt, DIE ZEIT, WirtschaftsWoche and Apotheken Umschau, and thus an enormous reach into the respective target groups. DvH Ventures was founded in 2014 and today manages various venture capital funds from its offices in Cologne and Vienna. Managing partners are Peter Richarz and Fabian von Trotha.

Mercia Asset Management PLC is a specialist asset manager focusing on supporting regional SMEs. The company provides capital across its four asset classes proprietary balance sheet capital, venture capital, private equity, and debt. The company initially nurtures businesses via its third-party funds under management and then, over time, provides further funding to the companies by deploying direct investment follow-on capital from its balance sheet. It has more than eight offices in the UK region, approx. 20 university partnerships and extensive personal networks, providing it with access to high-quality deal flow.